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Abstract
In this review, evidence is provided that apolipoprotein E (apoE) genotype accounts for the majority of Alzheimer’s disease (AD) risk
and pathology. The three major human isoforms, apoE2, apoE3, and apoE4, are encoded by different alleles (ε2, ε3, ε4) and regulate
lipid metabolism and redistribution. ApoE isoforms differ in their effects on AD risk and pathology. Clinical and epidemiological data
have indicated that the ε4 allele may account for 50% of AD in the United States. Further, the rarity of AD among carriers of the ε2
allele suggests that allelic variations in the gene encoding this protein may account for over 95% of AD cases. ApoE4 disrupts memory
function in rodents. Further studies have indicated that fragments of apoE may contribute to both plaque and tangle formation. Thus, the
epidemiologic and basic science evidence suggest that apoE genotype accounts for the vast majority of AD risk and pathology.
© 2004 Elsevier Inc. All rights reserved.
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1. The risk of AD increases in accordance with apoE
genotype such that E4 > E3 > E2
In 1993, a group lead by Alan Roses published a series
of papers suggesting that the ε4 allele of the gene encoding
apolipoprotein (apo) E has a major association with the risk
for Alzheimer’s disease (AD) [8,46,47,50,54]. In one paper,
Corder et al. [8], showed that the Estimated Onset of Distri-
bution is shifted to considerably younger ages in AD cases
with ε4/4 genotype (50% by age of onset of 66 y/o), than
the ε3/4 (50% by 73 y/o) or the ε3/3 (50% by 86 y/o), and
those without an ε4 and with an ε2 allele have an even later
age of onset.
2. Relative to apoE2, apoE3, and apoE4 may account
for 95% of the risk of AD
In a complimentary paper, Saunders et al. [49], presented
clinical data regarding the association of the ε4 allele with
AD suggesting that 50% of AD is associated with the ε4
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allele. Further, if the relative rarity of the disease among
ε2 homozygotes is considered, then the apoE genotype may
be seen as being responsible for as much as 95% of AD
(Table 1). These ﬁndings have been widely replicated (for
review, see [3]). However, the relationship between apoE
genotype and AD hazard (yearly incidence) has been con-
fused by studies which have examined populations over 65
years of age [11] and the diagnosis of autopsy conﬁrmed AD
without regard to age of onset [35]. Examination of the re-
lationship between apoE and AD with respect to age shows
that apoE genotype indeed accounts for most of the AD risk.
2.1. The central role of age in the development of AD
It has long been held that the major factor associated with
AD is aging, with family history playing a major secondary
role. Clearly, age is associated with AD, with estimations
that both the incidence and prevalence increase at an expo-
nential rate, such that the rates of disease occurrence start
at a very low level in middle age and double about every 5
years (most clearly between ages 60 and 90, Table 2 [28]).
There is some uncertainty as to whether this age-speciﬁc
rate varies between men and women (see below). The sug-
gestion that the rate may stabilize or decline over 90 years
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Table 1
ApoE genotype frequency in US population and AD risk
Genotype Populationa
(%)
ADb
(%)
#Population #AD Riskc
(%)
If all
US
ε2/2 1 0.1 0.5M 0.004M 0.08 0.4M
ε2/3 12 4 5.5M 0.18M 3.2 1.5M
ε3/3 60 35 27.6M 1.4M 5.1 2.3M
ε3/4 21 42 9.6M 1.7M 18 8.2M
ε4/4 2 16 0.9M 0.6M 67 30.7M
Please note that ε2/ε4 subjects are not included in table.
a Using estimate of 46 million in US over 60 y/o in 2000.
b Assuming 4 million individuals have AD.
c Data from [13,46,49].
of age has some support [38], but such “healthy survivor”
effects have been discussed at length and apply only to a
small number of individuals and may be measurement arti-
facts, mostly unrelated to AD diagnosis [21–23] or represent
the extreme limit of the aging process. Also, family history
shows a major association with the risk of developing AD,
even beyond the autosomal dominant mutations and apoE
genotype. The family risk that is not yet explained by ge-
netic factors could be related to unidentiﬁed genes associ-
ated with either AD risk or longevity to reach the age of
AD risk [52] or other manners of familial association such
as cultural factors. However, closer scrutiny of the actual
age of onset of dementia in AD patients in relationship to
the apoE genotype reveals that it is the APOE gene which
is the factor determining the vast majority of AD risk. This
association is modeled in detail below.
2.2. The Gompertz law and modeling biological aging
To examine the risk factors associated with the develop-
ment of AD, it is necessary to ﬁrst examine the process of
aging and the consequent mortality. Biological aging is the
reciprocal of decay and is associated with a progressive in-
crease in mortality rate with duration of life (as opposed
to a stable rate of mortality as would be seen in a decay
curve). Aging in biological systems may best be seen as a
consequence of the massive scale of redundancy achieved
by multi-cellular systems to compensate for the natural loss
of system elements over time [16], which is described by a
Gomperz curve (as opposed to a Weibull curve, as is seen for
Table 2
Prevalence of AD
Estimated 4 million cases in US (2000)
(2000–46 million individuals over 60 y/o)
Estimated 500,000 new cases per year
Increase with age (prevalence)
1% of 60–65 (10.7m) = 107,000
2% of 65–70 (9.4m) = 188,000
4% of 70–75 (8.7m) = 350,000
8% of 75–80 (7.4m) = 595,000
16% of 80–85 (5.0m) = 800,000
aging in mechanical systems, for reviews, see [16,21–23]).
TheGompertzlawstatesthatmortalitystartsatalowlevelin
early adulthood, and then doubles every set number of years.
There is an exponential increase of death rate beginning at
age 30, doubling every 7.5 years for women and every 8.2
years for men, with over 99.5% of the variance in mortal-
ity rate explained by an exponential function (a straight line
on log-linear plot, Fig. 1c) between 30 and 95 years of age
for the US population. Comparing AD incidence per year
data (Fig. 1c), it is apparent that the rate of developing AD
increases more rapidly (doubling every 5 years) than mor-
tality rate. The rate of developing AD would be expected to
exceed that of mortality by 105 years old (though there is
some difﬁculty in assessing such values in small, difﬁcult to
ﬁndpopulations).Withoutconsideringthecontroversyabout
whether there is a different rate of developing AD related to
gender (cf. [28]; and for the consideration that females are
more vulnerable to AD than males, see [13,64], application
of the rate of developing AD to the US Census data yields
the result that there is nearly twice as much AD in women
solely related to the increased longevity of women (Fig. 1d).
The centenary population (individuals in their 100th year)
only represents about 1% of the birth cohort (and there are
ﬁve times as many females at this age as there are males),
but, according to these calculations, 80% of centenarians
have AD (though the empirical data of Miech et al. [38],
support the ﬁndings of others that this level is not reached
in centenarians because of a plateau in the increasing rate at
very old age).
2.3. AD attacks brain systems with a high degree of
neuroplasticity
It is remarkable that the development of AD is more
closely related to aging than mortality is. This pattern of
age-accelerated AD development suggests that there is a
catastrophic breakdown of a selective brain system with age.
To show such a close relationship to aging, that system needs
tobehighlyredundantandcomposedofpartsthatmustreach
a threshold of dysfunction and then deteriorate very quickly.
In the case of AD, the redundant system is the network
of neurons subserving memory, and when the deterioration
of these neurons reaches the point that network capacity is
impaired, memory problems will appear, and then the pa-
tientwilldeterioraterelativelyrapidly.Thehighly-redundant
brain system that is attacked by AD pathology is thought
to be composed of those neuronal systems that have ma-
jor neuroplastic activity, which underlies memory function
[1–3,37,56].
2.4. Broad support for the relationship between ApoE
genotype and AD
Since the apoE genotype was ﬁrst shown to have a major
impact on the age of development of AD, there have been
over 100 studies which have conﬁrmed the relationshipJ. Raber et al./Neurobiology of Aging 25 (2004) 641–650 643
Fig. 1. (a) Census of the US, for 2000. Total: 281,421,906; >60: 45,809,291; >65: 35,003,844; >85: 4,251,678; >100: 62,545. (b) Mortality data from the
US, for 1999. (c) Mortality data by year of age using data from the US Center for Disease Control (http://www.cd.gov) divided by the US Census data
from the year 2000 (http://www.census.gov), to yield the yearly hazard rate for dying, according gender. The doubling times are calculated for the range
from 30 to 100 years of age by gender, where an exponential function with these parameters explains over 99.5% of the variance. The solid line shows the
estimated yearly hazard for developing AD, assuming a 5 year doubling rate and 4 million affected individuals in the population, with a life expectancy
from diagnosis of 8 years. (d) The number of patients estimated to contract Alzheimer’s disease each year, by sex (box) and by age (graph) in the US.
between AD and apoE genotype (a PubMed search
in November 2003 with “apoE and Alzheimer and
epidemiology” revealed 366 publications, most of which
support this ﬁnding and the few studies that did not ﬁnd the
relationship in selective populations contrasted their ﬁnd-
ings with other populations that did have the relationship).
However, the strength of this relationship varies among
epidemiological populations around the world, and it has
even been suggested that ε4 might not be a risk factor for
AD in some populations [13,20]. Many of the studies can
be broken down into two categories, those which examine
the prevalence of the disease in the clinical practice setting
and those that examine epidemiological samples. The clini-
cal studies are biased by the tendency of younger patients,
particularly those less than 75 years of age, to more vig-
orously seek help for their memory difﬁculties than very
elderly individuals with memory problems. Such studies
must contrast their ﬁndings with prevalence data from con-
trol populations, which may focus on young adults that have
not yet lived to the ages with the highest risk (Table 3a and
b); therefore, these individuals might still develop AD. Fur-
ther, apoE allele frequencies vary with populations around
the world (Table 3a), which can affect local estimates of
the contribution of these alleles to AD prevalence.
In contrast to the case-controlled studies, prospective epi-
demiological studies need to limit their populations to el-
derly groups in which AD will occur adequately often to
measure, e.g. all individuals over 65 years of age. However,
beginning a study with elderly unaffected individuals will
screen out the younger individuals with the at risk allele that
were highly likely to get AD at a younger age than the study
Table 3
ApoE genotype (a) in the US (world range)a and (b) prevalence in the
US (calculated from (a))
(a)
e2–7% of the population
e3–78% of the population (54%–91%)
(Pygmies–Sardinians)
e4–15% of the population (5%–41%)
(Mayans–Pygmies)
(b)
e2/2–0.5% of the population
e2/3–11% of the population
e2/4–2% of the population
e3/3–61% of the population
e3/4–23% of the population
e4/4–2% of the population
a Data from [15].644 J. Raber et al./Neurobiology of Aging 25 (2004) 641–650
criterion or the date of enrollment commencement. Also,
such epidemiological studies require dementia free status for
admission to the study, assuring the relative exclusion of the
individuals with high risk alleles, and thus, producing a sub-
stantial underestimation of the risk associated with apoE4
(e.g. [11]; see for review [3]). Accordingly, when studying
AD, one must focus not just on what the allele frequencies
are in the population, but how the gene-frequency changes
with age and with respect to the changing incidence of the
disease, which is related to the high rates at which the dis-
ease depletes the population of unaffected individuals.
2.5. Age-speciﬁc estimates of AD risk associated with
apoE genotype
For the purpose of modeling the problem of age and
changing AD risk with respect to apoE genotype, Gom-
pertz curves were constructed with the acceptance of the
estimation that AD incidence doubles every 5 years. It was
assumed (without supporting empirical data) that this same
Fig. 2. (a) The rate of development of AD by age for the total population (solid line, from Fig. 1c, mean rate), with estimated rates according to speciﬁc
ApoE genotypes, using data from Table 1. (b) Squares: males; circles: females; open: e4/4; gray: e3/4; ﬁlled: e3/3; age-speciﬁc risk × proportion of
original population at 50 years of age living at the age. (c) Estimate of population not affected by AD, by age, calculated from the rate estimates. (d)
Proportion of total non-demented patients estimated to develop AD at each age. Note that the ApoE ε4 allele plays a progressively smaller role as the
patients with this allele are eliminated from the at-risk population, ﬁrst the more susceptible homozygous patients, then the heterozygous patients.
rate would apply across all apoE genotypes. Further, the
data from Table 1 were used to approximate the relative
base-rates of the Gompertz curves, with the apoE ε4/4 geno-
type estimated to have a risk 7.5 times the mean, the ε3/4
to have two times the mean, and the ε3/3 genotype to have
0.6 times the mean (these are age-speciﬁc hazard factors
rather than odds ratios, which would depend on the sample
population; also, the risk may vary for gender differently
across the apoE genotypes, e.g. [13,38]. AD risk associated
with the apoE ε2 allele is considered to be much less, but is
not shown. The resulting curves show the relative estimate
of risk relative to age (Fig. 2a), the effect on the US popu-
lation of the 2000 Census for probability of AD onset in a
year (Fig. 2b), the probability of not having AD (Fig. 2c),
and the calculated estimate of the proportion of new AD
cases having each genotype according to age of disease
development (Fig. 2d). These graphs show that, given the
assumptions of the risk and the US population characteris-
tics, the 25% of the population with an ε4 allele accounts for
90% of the new AD cases until 80 years of age. While theseJ. Raber et al./Neurobiology of Aging 25 (2004) 641–650 645
Table 4
Ages of maximum probability of AD onset
Gompertz estimate (AD
probability per year)
Cache county data [38] (discrete
annual hazard of AD)a
Male
3/3 85 y/o x/x 92 y/o
3/4 83 x/4 91
4/4 78 4/4 78
Female
3/3 88 y/o x/x 97
3/4 86 x/4 96
4/4 80 4/4 83
a x = 2o r3 .
calculations are based on several assumptions, the only pop-
ulation study that shows data with this type of presentation
is from the Cache County Study, and the data presented by
that study show a relatively stronger inﬂuence of the ε4 al-
lele [38] than the relatively conservative assumptions used
to formulate the estimates shown here (see Table 4).
2.6. Further support for the association between apoE
genotype and AD risk
There are still several other points that support the above
estimates. For example, to the best of knowledge there is no
publication of an autopsy conﬁrmed case of an individual
with ε4/4 genotype over 90 years of age without AD. Also,
there is no publication claiming that an individual with ε2/2
genotype has had typical AD pathology without a separate
geneticorcleartraumaticantecedent(thatweknowof).Even
though the ε2 allele is nearly as common as the ε4 allele
in the population, and over-represented among centenarians
[14],therearerelativelyfewADpatientsstudiedwiththisal-
lele. Estimations of the evolution of the apoE genotype from
all ε4 to a majority of ε3 (which appeared 300,000 years ago
[15]) with a recent development of ε2 (200,000 years ago),
which occurred in parallel with a change of diet to include
more cholesterol and a progressive increase of longevity,
supports the relationship between improved memory in the
elderly and increased survival ﬁtness (see [56] for review).
Consequently, the epidemiological, clinical, and archeologi-
cal literature generally supports the point that the major risk
factor for AD is apoE ε4 allele, with the ε2 allele appearing
to be a protective factor. While there might be environmen-
tal factors, including diet, cholesterol, and hormones, which
may interact with the APOE gene and modulate its expres-
sion, they seem to account for a relative small proportion of
the variance. Accordingly, the apoE genotype represents the
major factor associated with the development of AD.
3. ApoE is associated with the pathological hallmarks
of AD, i.e. both plaques and tangles
The association of apoE immunoreactivity with amy-
loid  (A) peptides in extracellular plaques, intracellular
neuroﬁbrillary tangles (NFT), and cerebral vessel con-
gophilic angiopathy in brains of AD patients [41] suggests
a major role for apoE in the amyloid and neuritic pathology
in AD. Indeed, the severity of this pathology is inﬂuenced
by apoE genotype as illustrated below.
3.1. ApoE and Aβ
The presence of an ε4 allele increases the rate and extent
of amyloid deposition [10,50,54]. ApoE binds A with high
avidity. ApoE isoforms differ in their A binding charac-
teristics [54], and these different A binding characteristics
may contribute to the isoform-dependent effects of apoE on
amyloid deposition.
3.2. ApoE and neuroﬁbrillary tangles
While there is evidence for isoform-dependent effects of
apoE on neuroﬁbrillary pathology, these effects seem less
consistent than those on amyloid deposition (or plaque for-
mation) described above [10,17,50,54,61]. The percentage
of ε4 allele is higher in young subjects with initial neuroﬁb-
rillary pathology (Stage I) than in controls [17]. In addition,
this ε4 percentage correlates with the formation of neuroﬁb-
rillary pathology in non-demented elderly subjects [61] and
with neuroﬁbrillary pathology in AD subjects [36]. ApoE
binds tau and the differential ability of apoE isoforms to
bind tau [54] may contribute to the isoform-dependent ef-
fects of apoE on neuroﬁbrillary pathology. In general, the
effects of apoE isoforms on neuritic pathology parallel those
on A-related pathology. However, while AD patients with
the ε4/ε2 genotype showed signiﬁcantly less amyloid depo-
sition in the neocortex than those with ε4/ε3 genotype, the
neuroﬁbrillary pathology in these two genotypes was not
statistically signiﬁcant [40]. Similarly, comparing AD pa-
tients with the genotypes ε4/ε2 and ε3/ε2 showed opposite
effects on amyloid load and neuritic plaques and neuroﬁb-
rillary tangles [40]. The involvement of distinct mechanisms
involving interactions of apoE with A or tau could con-
tribute to these divergent effects on amyloid deposition and
neuroﬁbrillary pathology. As the clinical signs of AD are
more related to neuroﬁbrillary pathology than plaques [40],
ε2 would be expected to be more protective in the presence
of ε3 than ε4.
3.3. ApoE, progressive supranuclear palsy (PSP), and AD
pathology
ApoeE genotype also has an impact on AD pathology
when it occurs in patients that have other conditions, includ-
ing PSP and Down Syndrome. For example, most patients
with PSP have minimal or no AD pathology (Braak stage III
or less), but some patients do show AD pathology (plaques
and neuroﬁbrillary pathology) [59]. While the ε4 allele
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AD pathology (Braak stage III or less) (11%) and controls,
it is signiﬁcantly higher in PSP patients with concomitant
AD pathology (64%) or with pathologic aging (many cor-
tical senile plaques, mostly diffuse amyloid deposits, and
few or no neuroﬁbrillary tangles) (38%) [59]. Comparison
between ε4-positive and ε4-negative PSP patients shows
that ε4-positive PSP patients have signiﬁcantly more senile
plaques and neuroﬁbrillary tangles in association cortices
and more senile plaques in primary cortices.
4. In transgenic mice, expression of apoE4 causes
neuropathology and behavioral deﬁcits
4.1. Higher plaque loads in hAPP/E4 than in hAPP/E3
mice
Consistentwiththehumandatadescribedabove,apoEhas
isoform-dependent effects on plaque formation in transgenic
mice lacking murine apoE and expressing human amyloid
precursor protein with familial AD mutations (hAPP) and
human apoE isoforms in astrocytes [24] or neurons [6]. Im-
portantly, these mice express apoE3 and apoE4 at similar
levels and were shown to have comparable levels of A1-x
(approximation of total A) and A1–42 in the hippocam-
pus [44] at 6 months of age and neocortex at 12–15 months
of age [6].
4.2. ApoE4 and hAPP/apoE4 mice show loss of
synaptophysin-immunoreactive presynaptic terminals
Mice lacking murine apoE with and without hAPP
show a progressive age-dependent loss of synaptophysin-
immunoreactive presynaptic terminals. In human apoE
singly transgenic mice, apoE3 protects against this loss
but apoE4 does not. This protection is even seen at 19–24
months of age [6]. In hAPP/apoE bigenic mice, apoE3 is
able to delay the age-dependent decline in synaptophysin-
immunoreactive presynaptic terminals. At 6–7 months of
age, hAPP/apoE3 mice have signiﬁcantly higher levels of
synaptophysin-immunoreactive presynaptic terminals than
hAPP/apoE4 mice in the neocortex and at 12–15 months
of age in both hippocampus and cortex [6]. At 19–24
months of age, apoE3 is not protecting anymore against
the loss and the levels of synaptophysin-immunoreactive
presynaptic terminals at this age in hAPP, hAPP/apoE3,
and hAPP/apoE4 mice are comparable [6]. The isoform-
dependent effects of apoE on plaque loads do not correlate
with isoform-dependent effects of apoE on synaptophysin-
immunoreactive presynaptic terminals [6] or cognitive
function [44], supporting the possibility that apoE has also
important plaque-independent effects in AD. Consistent
with the human data, apoE2 is also neuroprotective; apoE2
prevented dendritic spine loss in the hippocampus of young
PDAPP and Tg2576 mice [31].
4.3. Neuronal expression of apoE4 increases
hyperphosphorylation of tau
Isoform-dependent effects of apoE with the microtubule-
associated proteins tau [54] and MAP2c have been reported,
suggesting a role for apoE in neuronal cytoskeletal function.
ApoE4 could contribute to AD pathology by hyperphospho-
rylation of cytoskeletal proteins and inducing neuroﬁbril-
lary pathology. Overexpression of apoE4 in neurons using
relatively strong promoters increased hyperphosphorylation
of tau, which was not seen when apoE4 was expressed in
non-neuronal cells, such as astrocytes [55]. The extent of
tau hyperphosphorylation correlated with apoE4 expression
levels and increased with age. In addition, in transgenic
mice expressing apoE4 in neurons but not in wild-type
mice ubiquitin-containing inclusions were observed in the
hippocampus, and prominent gliosis was observed in the
neocortex, hippocampus, and amygdala [55]. A recent study
suggests that increased tau phosphorylation in transgenic
mice expressing apoE4 in neurons might be caused by
the generation of carboxyl-terminal-truncated fragments of
apoE [19].
4.4. ApoE4 and cognitive function
ApoE has isoform-dependent effects on cognitive func-
tion in transgenic mice. As they age, female apoE4, but not
Apoe−/−, mice develop progressive impairments in spatial
learning and memory in the water maze [42,43]. These cog-
nitive impairments are independent of the cellular source of
apoE as they are observed in mice expressing apoE4 in neu-
rons or astrocytes. Spatial learning and memory are severely
impaired in AD and can be assessed in mice using the water
maze test. At 6 months of age, male and female Apoe−/−,
apoE3, and apoE4 mice learned to locate both the visible
and the hidden platform, and there were no signiﬁcant dif-
ferences in the learning curves. At 18 months of age, only
Apoe−/− (P<0.01) and apoE3 (P<0.05) females learned
to locate the hidden platform, whereas apoE4 females did
not. In the probe trial, 6- and 18-month-old female Apoe−/−
and apoE3 mice showed memory retention. They showed
an increased preference to search the quadrant where the
hidden platform was located previously (target quadrant). In
contrast, apoE4 females did not. ApoE4-induced cognitive
deﬁcits were detected even earlier using a modiﬁed version
of the water maze test, in which the platform location is hid-
den from the start and changed daily [42]. In this version
of the water maze, apoE4 females showed striking learn-
ing impairments by 6 months of age. Importantly, no spatial
learning deﬁcits were detected in age- and gender-matched
Apoe−/− mice in this more sensitive test. ApoE4 also ex-
erts detrimental effects on non-spatial learning and mem-
ory; 6-month-old male and female apoE4, apoE3, wildtype,
and Apoe−/− mice were assessed in a novel-object recog-
nition test. The percentage of time the mice spent explor-
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amount of time they explored either object in the retention
session was used to evaluate object recognition memory. In
the training session, all groups of mice spent a compara-
ble amount of time exploring each object. Female Apoe−/−
mice and all the other genotypes had intact object recog-
nition memory and spent signiﬁcantly more time exploring
the novel object. However, female apoE4 mice showed sig-
niﬁcant deﬁcits in the retention session and spent a signiﬁ-
cantly smaller proportion of time exploring the novel object.
These results demonstrate that apoE4 induces deﬁcits not
only in spatial but also in non-spatial learning and memory.
The greater detrimental effects of apoE4 in female than male
mice are consistent with the epidemiological interaction of
apoE4 and female gender on increased risk to develop AD.
However, male mice are only relatively protected against
the detrimental effects of apoE4. When tested for spatial
learning and memory in the water maze, male hAPP/apoE3
mice showed good memory retention but male hAPP and
hAPP/apoE4 mice failed to spend more time in the target
quadrant than in the other quadrants. Similar results were
obtained in female mice except that singly transgenic apoE4
female mice also failed to spend more time in the target
quadrant.
The beneﬁcial effects of environmental enrichment on
cognition are also dependent on apoE genotype; environ-
mental enrichment improves spatial learning and memory of
apoE3, but not apoE4, transgenic mice [32].
The effects of apoE4 on neuropathology and behavior in
mice are consistent with their effects on neuropathology and
behavior in humans. The neuropathological data in humans
supporting a crucial role for apoE4 in the neuropathological
hallmarks of AD are described above (see Section 3). With
regard to the behavioral data in humans, apoE4 increases
the risk of cognitive impairments and of developing AD
[8,9,13,45,64]. In addition, in cognitively non-demented
individuals, those with ε4 show reduced brain metabolism
and increased brain activation during recall [53]. Using
fMRI, women at risk for AD showed an increased parietal
activation during a ﬂuency task and upon retesting a further
decrease in ventral temporal lobe activation on a picture
naming task, as compared to a control group [60]. Finally,
apoE4 interacts with female gender, further increasing
AD risk in women [13,64]. This interaction might involve
androgen receptors. Using mice deﬁcient in mouse apoE
(Apoe−/−) and expressing human apoE4 or apoE3 in the
brain at comparable levels, apoE4 expression in female and
male mice reduced cytosolic AR levels in the neocortex
[44]. Male apoE4 mice might be less susceptible to effects
of apoE4 on DHT binding to ARs because of their higher
circulating levels of endogenous androgens. Importantly,
androgens and AR-dependent pathways protected against
detrimental effects of apoE4 on learning and memory in
female mice [44]. Improved memory in androgen-treated
female apoE4 mice was associated with increased binding
of DHT to cytosolic ARs, suggesting that apoE4 contributes
to cognitive decline by reducing DHT binding to ARs in
the brain and that stimulating AR-dependent pathways can
reverse apoE4-induced cognitive deﬁcits.
5. Plaque formation appears to require the presence of
apoE
5.1. Differential interaction of apoE isoforms with Aβ
peptides in vitro
Overproduction and deposition of A have been sug-
gested to play a central role in AD pathogenesis [18,51].I n
vitro,lipid-freeapoE3andapoE4canformasodiumdodecyl
sulfate (SDS)—and guanidine hydrochloride—stable com-
plex with A peptides, with apoE4 complexes forming more
rapidly and effectively [7,54]. Prolonged incubation (several
days) of lipid-free apoE with A peptide results in insol-
uble, high-molecular-weight complexes that precipitate as
ﬁbers. Again, apoE4 forms a denser, more extensive matrix
of amyloid monoﬁbrils and does so more rapidly and effec-
tively than apoE3 [33,48,62]. In addition, lipid-free apoE4
enhances zinc- and copper-induced A aggregation [39].
Thus, lipid-free apoE appears to display isoform-speciﬁc
differences in binding to the A peptide, with apoE4 bind-
ing more rapidly and effectively under certain conditions.
Increased amyloid ﬁbril formation associated with apoE4
might trigger or exacerbate neurodegeneration and the de-
velopment of AD.
However, when incubated with A peptide, lipidated
apoE3 or apoE4 isolated from stably transfected apoE-
expressing cells yielded different results [29,30]. ApoE3
bound with a 20-fold greater afﬁnity than apE4 to the A
peptide, suggesting that the lipidation status of apoE modi-
ﬁes its ability to interact with A peptides [29,30]. The avid
binding of lipidated apoE3 to the A peptide may enhance
clearance of the complex, preventing the conversion of A
into a neurotoxic species [30].
5.2. Plaque formation appears to require the presence of
ApoE in transgenic mice
Studies of transgenic mice expressing human apoE3
or apoE4 have provided insight into the role of apoE in
A metabolism in vivo. When transgenic mice expressing
human APP with a familial AD mutation (V717F) were
crossed onto an apoE-null background, A deposition in
the brain decreased dramatically, suggesting that apoE is
required for A deposition at least in transgenic mice [4,5].
A similar conclusion had been reached when transgenic
mice (Tg2576) expressing human APP with double muta-
tions (K670N and M671L) were crossed with apoE-null
mice [27]. However, expression of human apoE3 or apoE4
in the absence of mouse apoE further decreased A deposi-
tion, suggesting that human apoE stimulates A clearance
[12,24]. Interestingly, apoE3 might clear more A than
apoE4 [12,24].648 J. Raber et al./Neurobiology of Aging 25 (2004) 641–650
6. Proteolytic fragments of apoE may contribute both
to plaque and tangle formation
6.1. The carboxyl-terminal fragment of apoE may
contribute to plaque formation
It was ﬁrst reported that a carboxyl-terminal fragment
(residues 216–299) of apoE (the full-length apoE has 299
amino acids) was co-puriﬁed with A from senile plaques
[62,63].Invitro,thisfragmentfromrecombinantapoEcould
form amyloid-like ﬁbrils, which were Congo-red positive
[63]. These results suggest that senile plaques may con-
tain amyloid ﬁbrils formed from both A and the carboxyl-
terminalapoEfragment[62,63].Thus,thecarboxyl-terminal
fragment of apoE may contribute to plaque formation, al-
though the protease that cleaves apoE has not been identi-
ﬁed.
6.2. The amino-terminal 22-kDa thrombin-cleavage
fragment of apoE is neurotoxic in vitro
It was found that the amino-terminal 22-kDa thrombin-
cleavage fragment (amino acids 1–191) of apoE4 is more
neurotoxic than the corresponding fragment of apoE3
in vitro [57,58]. This neurotoxicity may be mediated by
lipoprotein receptors on the cell surface and by increasing
intracellular calcium levels through NMDA glutamate re-
ceptor [57,58]. The involvement of the lipoprotein receptors
in the 22-kDa thrombin-cleavage fragment of apoE-induced
neurotoxicity is supported by the observation that the syn-
thetic peptides of the LDL receptor binding domain of apoE
is also neurotoxic in vitro [57,58]. However, subsequent
study suggests that the apoE fragments generated in AD
brains are different from the 22-kDa thrombin-cleavage
products [25]. In fact, the lipid-binding domain (amino
acids 244–272) is present in all the fragments generated
in AD brains [25] and is essential for the development of
neurotoxicity in transgenic mice [19].
6.3. The carboxyl-terminal-truncated fragments of apoE
accumulate in AD brains and can induce NFT-like
inclusions in neuronal cells in vitro
ApoE4 is more susceptible to proteolytic cleavage than
apoE3 in vitro [19,25]. Notably, apoE fragments were also
present at much higher levels in brains of AD patients than
in brains of age- and sex-matched non-demented controls
with the corresponding apoE genotypes [19,25]. Carboxyl-
terminal-truncated fragments of apoE also appeared to ac-
cumulate in neuroﬁbrillary tangles in AD brains [19].I n
vitro, the carboxyl-terminal-truncated fragments of apoE are
toxic when expressed in neuronal cells or added to neu-
ronal cultures, leading to cell death and to the formation of
cytoplasmic NFT-like inclusions in some of the cells [19].
Thus, the carboxyl-terminal-truncated apoE may contribute
to NFT formation [26,34].
6.4. The carboxyl-terminal-truncated apoE4 causes
AD-like neuronal and behavioral deﬁcits in transgenic mice
Transgenic mice expressing high levels of the carboxyl-
terminal-truncated apoE4 [apoE4( 272–299)] died at
2–4 months of age [19]. The cortex and hippocampus
of these mice displayed AD-like neurodegenerative alter-
ations, including abnormally phosphorylated tau (p-tau)
and Gallyas silver-positive neurons containing cytosolic
straight ﬁlaments with diameters of 15–20nm, resembling
pre-neuroﬁbrillary tangles. Transgenic mice expressing
lower levels of the truncated apoE4 survived longer but
showed impaired learning and memory at 6–7 months [19].
Thus, carboxyl-terminal-truncated fragments of apoE4,
which occur in AD brains, are sufﬁcient to elicit AD-like
neurodegeneration and behavioral deﬁcits in vivo [19].
7. Summary
Thisreviewhasconcentratedontheevidencethatsupports
the relationship between apoE genotype and AD risk. The
apoE molecule has been shown to be associated with several
factorsthatleadtoADpathology.Inthecontextofthedebate
about the association between apoE genotype and AD, it has
been shown that this genotype can independently account
for as much as 95% of the AD cases in the US. Another
consideration is that apoE-ε2 homozygotes may not even
develop AD in the absence of other speciﬁc, rare genetic or
environmental factors. Therefore, the apoE genotype may
be considered to be responsible for the vast majority of AD.
The dominant role of apoE needs to be considered in a
broader context. For example, those individuals with apoE
ε3 and/or ε4 alleles have a risk for AD that is age- and
gender-related, and there are other factors, including head-
trauma and diet, that can affect the age of onset of AD
in these individuals. Further, certain interventions, possibly
including NSAID or statin use, may substantially change
age of onset, and some of these interventions may differ in
their impact, depending on apoE genotype.
The overwhelming role of apoE genotype in AD argues
that this genetic factor should be studied in greater depth
for how it can be used chemically to improve early detec-
tion and diagnosis of AD, as well as how information about
this genotype can improve prevention and early intervention
strategies. However, the importance of apoE does not lessen
the importance of other known and unknown factors that
could also play important roles in preventing AD or improv-
ing the treatment of patients with this important condition.
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